ATE356635T1 - Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen - Google Patents

Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen

Info

Publication number: ATE356635T1
Authority: AT; Austria
Prior art keywords: benigus; treating; preventing; gynecological disorders; progestogen
Prior art date: 2001-11-15

Application number

AT02780166T

Other languages

English (en)

Inventor

Bennink Herman Jan Ti Coelingh

Monique Visser

Original Assignee

Pantarhei Bioscience Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-15

Filing date

2002-11-14

Publication date

2007-04-15

2002-11-14 Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv

2007-04-15 Application granted granted Critical

2007-04-15 Publication of ATE356635T1 publication Critical patent/ATE356635T1/de

Links

239000000583 progesterone congener Substances 0.000 abstract 3
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 2
229960004400 levonorgestrel Drugs 0.000 abstract 2
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 abstract 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
229960003309 dienogest Drugs 0.000 abstract 1
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
229960004845 drospirenone Drugs 0.000 abstract 1
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
229960004913 dydrogesterone Drugs 0.000 abstract 1
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 abstract 1
229960002568 ethinylestradiol Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229940053934 norethindrone Drugs 0.000 abstract 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 abstract 1
229960000417 norgestimate Drugs 0.000 abstract 1
229960002847 prasterone Drugs 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 abstract 1
229950008546 trimegestone Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02780166T 2001-11-15 2002-11-14 Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen ATE356635T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01204379		2001-11-15

Publications (1)

Publication Number	Publication Date
ATE356635T1 true ATE356635T1 (de)	2007-04-15

Family

ID=8181247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02780166T ATE356635T1 (de)	2001-11-15	2002-11-14	Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen

Country Status (10)

Country	Link
US (2)	US8071576B2 (de)
EP (1)	EP1443966B1 (de)
AT (1)	ATE356635T1 (de)
CA (1)	CA2467237C (de)
CY (1)	CY1106610T1 (de)
DE (1)	DE60218881T2 (de)
DK (1)	DK1443966T3 (de)
ES (1)	ES2281551T3 (de)
PT (1)	PT1443966E (de)
WO (1)	WO2003041741A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001030356A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
IL162533A0 (en) *	2001-12-19	2005-11-20	Atherogenics Inc	Chalcone derivatives and their use to treat diseases
KR101863136B1 (ko)	2008-01-24	2018-05-31	에스퍼란스 파마슈티컬스, 인코포레이티드	용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
US20130260460A1 (en)	2010-04-22	2013-10-03	Isis Pharmaceuticals Inc	Conformationally restricted dinucleotide monomers and oligonucleotides
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
BRPI1003661A2 (pt) *	2010-09-15	2013-01-08	Libbs Farmacêutica Ltda	associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
RS62297B1 (sr)	2011-11-23	2021-09-30	Therapeuticsmd Inc	Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
WO2014070957A1 (en)	2012-10-30	2014-05-08	Esperance Pharmaceuticals, Inc.	Antibody/drug conjugates and methods of use
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3608075A (en) *	1969-07-28	1971-09-21	American Home Prod	Compositions and methods of treating the menopausal syndrome
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
ZA924811B (en)	1991-06-28	1993-12-29	Endorecherche Inc	Controlled release systems and low dose androgens
EP0680327B1 (de) *	1993-01-19	2004-09-15	Endorecherche Inc.	Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US6139873A (en) *	1996-07-10	2000-10-31	Cedars-Sinai Medical Center	Combined pharmaceutical estrogen-androgen-progestin
GB9616700D0 (en) *	1996-08-09	1996-09-25	Carey Beverly J	Hormone supplement
US6117446A (en) *	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
CA2446849A1 (en) *	2001-05-16	2002-11-21	Endeavor Pharmaceuticals	Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030022875A1 (en) *	2001-07-27	2003-01-30	Wilson Leland F.	As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness

2002
- 2002-11-14 ES ES02780166T patent/ES2281551T3/es not_active Expired - Lifetime
- 2002-11-14 CA CA2467237A patent/CA2467237C/en not_active Expired - Lifetime
- 2002-11-14 DE DE60218881T patent/DE60218881T2/de not_active Expired - Lifetime
- 2002-11-14 EP EP02780166A patent/EP1443966B1/de not_active Expired - Lifetime
- 2002-11-14 DK DK02780166T patent/DK1443966T3/da active
- 2002-11-14 US US10/495,708 patent/US8071576B2/en active Active
- 2002-11-14 AT AT02780166T patent/ATE356635T1/de active
- 2002-11-14 PT PT02780166T patent/PT1443966E/pt unknown
- 2002-11-14 WO PCT/NL2002/000733 patent/WO2003041741A1/en not_active Ceased
2007
- 2007-05-21 CY CY20071100683T patent/CY1106610T1/el unknown
2011
- 2011-09-23 US US13/242,034 patent/US20120015917A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1443966B1 (de)	2007-03-14
PT1443966E (pt)	2007-06-21
DE60218881T2 (de)	2007-12-20
CA2467237A1 (en)	2003-05-22
ES2281551T3 (es)	2007-10-01
CA2467237C (en)	2011-09-20
WO2003041741A1 (en)	2003-05-22
DK1443966T3 (da)	2007-05-21
CY1106610T1 (el)	2012-01-25
US8071576B2 (en)	2011-12-06
EP1443966A1 (de)	2004-08-11
US20120015917A1 (en)	2012-01-19
DE60218881D1 (de)	2007-04-26
US20050148559A1 (en)	2005-07-07

Similar Documents

Publication	Publication Date	Title
DE60218881D1 (de)	2007-04-26	Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
JP2019163318A5 (de)	2020-09-24
AR049112A1 (es)	2006-06-28	Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
ATE493132T1 (de)	2011-01-15	Arzneimittel umfassend wenigstens ein gestagen
EA200600964A1 (ru)	2006-10-27	Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
RU2007148080A (ru)	2009-08-10	Составы и способы для лечения симптомов, связанных с циклом
DE59510069D1 (de)	2002-03-28	Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri
KR970704451A (ko)	1997-09-06	기능부전성 자궁출혈 치료용 약제의 제조에 유용한 프로게스테론 길항제(Progesterone Antagonists Useful for Preparing Medicaments for Treating Dysfunctional Uterine Bleeding)
BR9710566A (pt)	1999-08-17	M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
DE60115274D1 (de)	2005-12-29	Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
ATE270554T1 (de)	2004-07-15	Kombination der progesteron und mifepristone für krebs-therapie
CO5580789A2 (es)	2005-11-30	Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis
DE69724796D1 (de)	2003-10-16	Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
EP1286666B1 (de)	2005-01-12	Starterkit von niedrigdosiertem oralem kontrazeptiv
RU2000115313A (ru)	2002-06-20	Схемы приема гестаген-анти-гестагена
DE60230936D1 (de)	2009-03-05	Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen
CN101237836A (zh)	2008-08-06	用于避孕的药物控释装置的新方案
ATE395047T1 (de)	2008-05-15	Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
BRPI0511864A (pt)	2008-01-22	uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
ATE319733T1 (de)	2006-03-15	4-halogenierte 17-methylensteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
TW200640468A (en)	2006-12-01	Pharmaceutical product for oral contraception
Robb-Nicholson	2000	By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
CY1112775T1 (el)	2016-02-10	Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
JP2005518412A5 (de)	2006-03-16
TH55261A (th)	2003-02-26	การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1443966

Country of ref document: EP